Alexandrina P.
- Country
- Romania
- Department
- Diabet zaharat, nutritie si boli metabolice
Research Overview
- Phase III Study of RO7795068 in Adults With Obesity or Overweight and Type 2 Diabetes
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Phase 3 Randomized, Placebo-Controlled Study on the Efficacy and Safety of Zalunfiban in Pre-Hospital ST-Elevation Myocardial Infarction Patients
Data & Insights
Has run more than one trial at 301 of 1055 partner sites.
Specializations
Cardiometabolic Disease
Clinical research activity includes type 2 diabetes, type 1 diabetes, overweight, obesity, and atherosclerotic cardiovascular disease, with interest in therapies that address both glycaemic control and cardiovascular risk.
- Type 2 diabetes mellitus
- Obesity and overweight
- Cardiovascular risk reduction
The therapeutic scope also extends to metabolic treatment strategies in people with established cardiovascular disease and comorbid weight-related disorders.
Heart Failure
Research involvement is centered on chronic heart failure, worsening heart failure, heart failure with preserved ejection fraction, and heart failure with mildly reduced ejection fraction, including patients with systemic inflammation or kidney impairment.
- Chronic heart failure
- HFpEF and HFmrEF
- Heart failure with kidney dysfunction
Therapeutic interest also includes prevention of heart failure events and management of cardiovascular death risk in high-risk populations.
Thrombosis and Anticoagulation
Clinical trial activity covers atrial fibrillation, prevention of stroke and systemic embolism, and reversal of anticoagulant effects in urgent surgical settings.
- Atrial fibrillation
- Stroke prevention
- Anticoagulation reversal
Additional interest includes acute coronary syndrome, STEMI, and hemostatic support in patients requiring cardiac or non-cardiac procedures.
Pulmonary Vascular Disease
Research participation includes pulmonary arterial hypertension, pulmonary hypertension, and PH-HFpEF, with attention to functional status, vascular resistance, and long-term disease control.
- Pulmonary arterial hypertension
- Pulmonary hypertension
- PH-HFpEF
Therapeutic focus also includes advanced treatment approaches for group I pulmonary arterial hypertension and follow-up care in chronic pulmonary vascular disease.
Cardiorenal and Structural Heart Disorders
Investigated conditions also include chronic kidney disease, hypertension, transthyretin amyloidosis with cardiomyopathy, and iron-deficient chronic heart failure, reflecting interest in overlapping cardiac and renal disease states.
- Chronic kidney disease
- Hypertension
- Transthyretin amyloidosis with cardiomyopathy
Medical interest further includes therapies for cardiorenal syndrome and structural myocardial disease associated with progressive cardiovascular dysfunction.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.